Company Comparison
Alnylam vs 54gene
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Alnylam | 54gene |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Cambridge, Massachusetts | Lagos, Nigeria |
| Founded | 2002 | 2019 |
| Status | Active | Active |
| Last Funding Stage | — | Series B |
| Total Funding | — | $45M |
| Valuation | — | — |
What They Build
Alnylam
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
54gene
African genomics research company advancing precision medicine through genetic research focused on African populations.
Key Investors
Sector Overlap
Both Alnylam and 54gene operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.